• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies

  • Print
  • Share
  • E-mail
-
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH

DIVISION OF EPIDEMIOLOGY

"PROTECTING & PROMOTING PUBLIC HEALTH THROUGH DEVICE SURVEILLANCE AND RESEARCH"



WELCOME TO THE 522 POSTMARKET SURVEILLANCE STUDIES WEBPAGE

 

 

 

 

            

Sampling and Culturing Study


 
Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Noncompliant
522 Number / Requirement Number PS150002 / PSS002
Date Current Plan Accepted 12/21/2016
Study Name Sampling and Culturing Study
Root Document Number K944759  K944620  K042076 
General Study Protocol Parameters
Study Design Bench/Lab Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population
Detailed Study Protocol Parameters
Study Design Description This is the pilot phase (phase 1) of the Sampling and Culturing Study for Fujifilm. This is a laboratory study in which clinically used duodenoscopes will be reprocessed, sampled, and cultured for microbial growth. Duodenoscopes are flexible side-viewing gastrointestinal endoscopes used in patients undergoing ERCP procedures to address problems with the bile ducts or pancreatic ducts.



The objectives of this pilot phase are as follows:

1. Identify clinical sites to collect duodenoscope samples and identify laboratories for culturing those samples.

2. Train staff on sampling and culturing protocols.

3. Pilot the sampling and culturing protocols to identify errors and inefficiencies in the pilot protocols which will allow for streamlining of the sampling and culturing protocols during the pivotal phase (phase 2) of the study.



Study Population Description The study population consists of Fujifilm model ED-530XT duodenoscopes that have been used in ERCP procedures and reprocessed by trained healthcare facility staff in accordance with the duodenoscope reprocessing manual. Duodenoscopes will be subjected to sampling following completion of the cleaning and manual disinfection or disinfection using any of the following automated endoscope reprocessors (AERs):

• ASP EvoTech ECR

• Medivators Advantage Plus

• Medivators DSD Edge

• Steris Corporation System 1E Liquid Chemical Sterilant Processing System

Sample Size Max # of Pilot

Install Samples Min # of Sample

Base per Scope Scopes Size .

214 30 3 85



Data Collection The primary endpoint of the pilot phase is successful completion of duodenoscope sampling and culturing, where the duodenoscope samples were collected from clinically used duodenoscopes from the identified healthcare facilities. Although the expectation is that none of the duodenoscope samples should be positive for high concern organisms or

have > 100 CFU of low/moderate concern organisms, a thorough investigation to identify the root causes of positive samples will be conducted for any positive sample.



Interim or Final Data Summary
Interim Safety Information As of the interim report dated March 18, 2019:



# of Sites Enrolled: 2

Total # of Samples Required: 727

# of Samples Analyzed: 104 (14%)



# of Samples Positive for Low Concern Organisms >100 CFU: 1/104 (1.0%) *

# of Samples Positive for High Concern Organisms: 2/104 (1.9%) *

* Fujifilm culturing results for samples collected using sterile methods (“properly collected”).



High concern organisms are defined as organisms that are more often associated with disease. Examples of high concern organisms include Gram-negative rods (e.g., Escherichia coli, Klebsiella pneumoniae or other Enterobacteriaceae as well as Pseudomonas aeruginosa), Staphylococcus aureus, Beta-hemolytic Streptococcus, Enterococcus species, and yeasts.



Sampling and Culturing Study Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
1 month report 01/20/2017 01/19/2017 On Time
2 month report 02/19/2017 02/17/2017 On Time
3 month report 03/21/2017 03/21/2017 On Time
4 month report 04/20/2017 04/20/2017 On Time
5 month report 05/20/2017 05/19/2017 On Time
6 month report 06/19/2017 06/19/2017 On Time
7 month report 07/19/2017 07/19/2017 On Time
8 month report 08/18/2017 08/18/2017 On Time
9 month report 09/17/2017 09/15/2017 On Time
10 month report 10/17/2017 10/17/2017 On Time
11 month report 11/16/2017 11/16/2017 On Time
1 year report 12/21/2017 12/21/2017 On Time
13 month report 01/20/2018 01/19/2018 On Time
14 month report 02/19/2018 02/20/2018 On Time
15 month report 03/21/2018 03/22/2018 On Time
16 month report 04/20/2018 04/20/2018 On Time
17 month report 05/18/2018 05/21/2018 On Time
18 month report 06/19/2018 06/19/2018 On Time
19 month report 07/19/2018 07/19/2018 On Time
20 month report 08/18/2018 08/17/2018 On Time
21 month report 09/17/2018 09/17/2018 On Time
22 month report 10/17/2018 10/17/2018 On Time
23 month report 11/17/2018 11/16/2018 On Time
24 month report 12/17/2018 12/17/2018 On Time
25 month report 01/17/2019 01/17/2019 On Time
26 month report 02/16/2019 02/15/2019 On Time
unsolicited INTERIM report 03/11/2019 03/11/2019 On Time
27 month report 03/18/2019 03/18/2019 On Time
28 month report 04/17/2019 04/17/2019 On Time
29 month report 05/17/2019    
30 month report 06/16/2019    
31 month report 07/16/2019    
32 month report 08/15/2019    


  • The 522 Postmarket Surveillance Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated under section 522 of the Federal Food, Drug and Cosmetic Act. The program helps ensure that well-designed 522 postmarket surveillance (PS) studies are conducted effectively and efficiently and in the least burdensome manner.
  • In May 2008, the oversight responsibility of the 522 Postmarket Surveillance Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH). DEPI continues to build the 522 program.
  • CDRH has established an automated internal tracking system that efficiently identifies the reporting status of active 522 PS studies based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all 522 PS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each 522 PS study. The webpage displays general information regarding each study, as well as the overall study status (based on protocol-driven timelines and adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Cheryl Reynolds
Project Manager, 522 Postmarket Surveillance (PS) Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-2252
Silver Spring, MD 20993-0002

Phone: (301) 796-6068
Fax: (301) 847-8140
Cheryl.Reynolds@fda.hhs.gov
-
-